Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP,Chief Med.Offr.,Drug Dev. | April 25, 2025 | April 29, 2025 |
| Iambic Therapeutics, Inc.IAM · Entity 184417 | Director | October 14, 2026 | October 14, 2026 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date April 25, 2025 · Filed April 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 83,513.486 |
Reported balance
After 2025-04-25 transaction · row 1
1 source rowRow 1 · 2025-04-25 · Purchase · Acquired 4,250 · Balance 83,513.486 |
Iambic Therapeutics, Inc.
Report date October 14, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.47 · Expires 2036-08-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Twenty-five percent of the shares subject to the option vest on August 10, 2027 and 1/48th of the shares vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent of the shares subject to the option vest on August 10, 2027 and 1/48th of the shares vest monthly thereafter.
Pacira BioSciences, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,405 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 6,405 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10 | Direct | 10,891 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 21:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,891 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001628280-26-043010 · wk-form4_1781312871.xml · derivative · entry 2 Hirawat Samit · CIK 0001781290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,891 Underlying: Common Stock · 10,891 shares Expires 2036-06-10 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-043010 · wk-form4_1781312871.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,405 F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 16:57 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 39,291 | $0.00 Strike: $19.85 | $0.00 |
DisclosureSEC source: 0001628280-26-004188 · wk-form4_1769723829.xml · derivative · entry 1 Hirawat Samit · CIK 0001781290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,291 Underlying: Common Stock · 39,291 shares Expires 2036-01-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 22:14 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | PurchaseCommon Stock, $0.10 par value | 4,250 | $47.58 | $202,215.00 |
DisclosureSEC source: 0000014272-25-000093 · wk-form4_1745964847.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,513.486 Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 52,720 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · derivative · entry 18 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,720 Underlying: Common Stock, $0.10 par value · 52,720 shares Expires 2028-03-10 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 28,593 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · derivative · entry 17 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 28,593 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: Each performance share converted into one share of common stock upon distribution in the first quarter of 2025 in accordance with the terms of the award and certification of performance results by the Board. F6 · derivative.exercise_date: Amount represents distribution of performance shares earned under the 2022-2024 Long-Term Performance Award. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 35,146 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · derivative · entry 16 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,146 Underlying: Common Stock, $0.10 par value · 35,146 shares Expires 2028-03-10 F10 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F11 · derivative.exercise_date: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 5,854 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · derivative · entry 15 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,711 Underlying: Common Stock, $0.10 par value · 5,854 shares Expires 2027-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F5 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2023. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · derivative · entry 14 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,767 Underlying: Common Stock, $0.10 par value · 4,765 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,886 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · derivative · entry 13 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 4,886 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 9,232 | $63.11 | $582,631.52 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 12 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,263.486 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 10,545 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 11 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,495.486 F7 · shares: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 28,593 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 10 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,040.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Amount represents distribution of performance shares earned under the 2022-2024 Long-Term Performance Award. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,484 | $63.11 | $156,765.24 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 9 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,447.486 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 998 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 8 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,931.486 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 5,854 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 7 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,929.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2023. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,013 | $63.11 | $127,040.43 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 6 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,075.486 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 831 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 5 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,088.486 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 4 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,919.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,327 | $63.11 | $146,856.97 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,154.486 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 337 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,481.486 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,886 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000063 · wk-form4_1741829424.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,818.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | PurchaseCommon Stock, $0.10 par value | 1,823.486 | $54.84 | $99,999.97 |
DisclosureSEC source: 0000014272-25-000041 · wk-form4_1740010788.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,932.486 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 22:41 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | PurchaseCommon Stock, $0.10 par value | 1,830 | $54.68 | $100,055.25 |
DisclosureSEC source: 0000014272-24-000149 · wk-form4_1730846476.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,109 Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 60,952 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · derivative · entry 16 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,952 Underlying: Common Stock, $0.10 par value · 60,952 shares Expires 2027-03-10 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2027. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2027. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 29,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · derivative · entry 15 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 29,311 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return. F12 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 40,635 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · derivative · entry 14 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,635 Underlying: Common Stock, $0.10 par value · 40,635 shares Expires 2028-03-10 F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F10 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherMarket Share Units · Derivative | 5,854 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · derivative · entry 13 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,565 Underlying: Common Stock, $0.10 par value · 5,854 shares Expires 2027-03-10 F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F11 · shares: Represents the cancellation of one-quarter of market share units granted on March 10, 2023 due to the 80% minimum payout factor not being achieved. F10 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherMarket Share Units · Derivative | 4,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · derivative · entry 12 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,532 Underlying: Common Stock, $0.10 par value · 4,765 shares Expires 2026-03-10 F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F9 · shares: Represents the cancellation of one-quarter of market share units granted on March 10, 2022 due to the 80% minimum payout factor not being achieved. F10 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · derivative · entry 11 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,886 Underlying: Common Stock, $0.10 par value · 4,885 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · derivative · entry 10 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 4,192 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 9,774 | $53.79 | $525,743.46 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 9 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,279 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 10,203 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 8 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,053 F6 · shares: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 29,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 7 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents distribution of performance shares earned under the 2021-2023 Long-Term Performance Award. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,068 | $53.79 | $111,237.72 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 6 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,945 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 842 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 5 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,013 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 4 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,807 | $53.79 | $97,198.53 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,970 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,777 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000070 · wk-form4_1710290395.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 21:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 9,357 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000128 · wk-form4_1688592218.xml · derivative · entry 3 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 9,357 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: The restricted stock units vest in four equal installments beginning on July 1, 2020. F1 · derivative.exercise_date: The restricted stock units vest in four equal installments beginning on July 1, 2020. F1 · derivative.expiration_date: The restricted stock units vest in four equal installments beginning on July 1, 2020. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 21:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,787 | $63.95 | $306,128.65 |
DisclosureSEC source: 0000014272-23-000128 · wk-form4_1688592218.xml · nonDerivative · entry 2 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,245 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 21:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 9,357 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000128 · wk-form4_1688592218.xml · nonDerivative · entry 1 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units vest in four equal installments beginning on July 1, 2020. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 35,129 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · derivative · entry 18 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,129 Underlying: Common Stock, $0.10 par value · 35,129 shares Expires 2026-03-10 F12 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2026. F12 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2026. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 25,139 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · derivative · entry 17 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 25,139 shares Expires 2023-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2023, subject to a Total Shareholder Return. F11 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2023, subject to a Total Shareholder Return. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 23,419 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · derivative · entry 16 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,419 Underlying: Common Stock, $0.10 par value · 23,419 shares Expires 2027-03-10 F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F10 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · derivative · entry 15 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,297 Underlying: Common Stock, $0.10 par value · 4,765 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F5 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · derivative · entry 14 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,771 Underlying: Common Stock, $0.10 par value · 4,885 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · derivative · entry 13 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,192 Underlying: Common Stock, $0.10 par value · 4,189 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| March 10, 2023 Filed Mar 15, 2023 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 14,429 | $65.71 | $948,129.59 |
DisclosureSEC source: 0000014272-23-000064 · wf-form4_167883950491167.xml · nonDerivative · entry 12 Hirawat Samit · CIK 0001781290 · EVP,Chief Med.Offr.,Drug Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,675 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.